Liquid biopsy to monitor melanoma patients

Maria Rita Gaiser; Nikolas von Bubnoff; Christoffer Gebhardt; Jochen Sven Utikal

doi:10.1111/ddg.13461

Liquid biopsy to monitor melanoma patients

Standard

Liquid biopsy to monitor melanoma patients. / Gaiser, Maria Rita; von Bubnoff, Nikolas; Gebhardt, Christoffer; Utikal, Jochen Sven.

in: J DTSCH DERMATOL GES, Jahrgang 16, Nr. 4, 04.2018, S. 405-414.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Gaiser, MR, von Bubnoff, N, Gebhardt, C & Utikal, JS 2018, 'Liquid biopsy to monitor melanoma patients', J DTSCH DERMATOL GES, Jg. 16, Nr. 4, S. 405-414. https://doi.org/10.1111/ddg.13461

APA

Gaiser, M. R., von Bubnoff, N., Gebhardt, C., & Utikal, J. S. (2018). Liquid biopsy to monitor melanoma patients. J DTSCH DERMATOL GES, 16(4), 405-414. https://doi.org/10.1111/ddg.13461

Vancouver

Gaiser MR, von Bubnoff N, Gebhardt C, Utikal JS. Liquid biopsy to monitor melanoma patients. J DTSCH DERMATOL GES. 2018 Apr;16(4):405-414. https://doi.org/10.1111/ddg.13461

Bibtex

@article{70d8d1cc629b48978189cab635ca5e5e,

title = "Liquid biopsy to monitor melanoma patients",

abstract = "During the last six years, several innovative, systemic therapies for the treatment of metastatic malignant melanoma (MM) have emerged. Conventional chemotherapy has been superseded by novel first-line therapies, including systemic immunotherapies (anti-CTLA4 and anti-PD1; authorization of anti-PDL1 is anticipated) and therapies targeting specific mutations (BRAF, NRAS, and c-KIT). Thus, treating physicians are confronted with new challenges, such as stratifying patients for appropriate treatments and monitoring long-term responders for progression. Consequently, reliable methods for monitoring disease progression or treatment resistance are necessary. Localized and advanced cancers may generate circulating tumor cells and circulating tumor DNA (ctDNA) that can be detected and quantified from peripheral blood samples (liquid biopsy). For melanoma patients, liquid biopsy results may be useful as novel predictive biomarkers to guide therapeutic decisions, particularly in the context of mutation-based targeted therapies. The challenges of using liquid biopsy include strict criteria for the phenotypic nature of circulating MM cells or their fragments and the instability of ctDNA in blood. The limitations of liquid biopsy in routine diagnostic testing are discussed in this review.",

keywords = "Journal Article, Review",

author = "Gaiser, {Maria Rita} and {von Bubnoff}, Nikolas and Christoffer Gebhardt and Utikal, {Jochen Sven}",

note = "{\textcopyright} 2018 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.",

year = "2018",

month = apr,

doi = "10.1111/ddg.13461",

language = "English",

volume = "16",

pages = "405--414",

journal = "J DTSCH DERMATOL GES",

issn = "1610-0379",

publisher = "Wiley-Blackwell",

number = "4",

}

RIS

TY - JOUR

T1 - Liquid biopsy to monitor melanoma patients

AU - Gaiser, Maria Rita

AU - von Bubnoff, Nikolas

AU - Gebhardt, Christoffer

AU - Utikal, Jochen Sven

PY - 2018/4

Y1 - 2018/4

N2 - During the last six years, several innovative, systemic therapies for the treatment of metastatic malignant melanoma (MM) have emerged. Conventional chemotherapy has been superseded by novel first-line therapies, including systemic immunotherapies (anti-CTLA4 and anti-PD1; authorization of anti-PDL1 is anticipated) and therapies targeting specific mutations (BRAF, NRAS, and c-KIT). Thus, treating physicians are confronted with new challenges, such as stratifying patients for appropriate treatments and monitoring long-term responders for progression. Consequently, reliable methods for monitoring disease progression or treatment resistance are necessary. Localized and advanced cancers may generate circulating tumor cells and circulating tumor DNA (ctDNA) that can be detected and quantified from peripheral blood samples (liquid biopsy). For melanoma patients, liquid biopsy results may be useful as novel predictive biomarkers to guide therapeutic decisions, particularly in the context of mutation-based targeted therapies. The challenges of using liquid biopsy include strict criteria for the phenotypic nature of circulating MM cells or their fragments and the instability of ctDNA in blood. The limitations of liquid biopsy in routine diagnostic testing are discussed in this review.

AB - During the last six years, several innovative, systemic therapies for the treatment of metastatic malignant melanoma (MM) have emerged. Conventional chemotherapy has been superseded by novel first-line therapies, including systemic immunotherapies (anti-CTLA4 and anti-PD1; authorization of anti-PDL1 is anticipated) and therapies targeting specific mutations (BRAF, NRAS, and c-KIT). Thus, treating physicians are confronted with new challenges, such as stratifying patients for appropriate treatments and monitoring long-term responders for progression. Consequently, reliable methods for monitoring disease progression or treatment resistance are necessary. Localized and advanced cancers may generate circulating tumor cells and circulating tumor DNA (ctDNA) that can be detected and quantified from peripheral blood samples (liquid biopsy). For melanoma patients, liquid biopsy results may be useful as novel predictive biomarkers to guide therapeutic decisions, particularly in the context of mutation-based targeted therapies. The challenges of using liquid biopsy include strict criteria for the phenotypic nature of circulating MM cells or their fragments and the instability of ctDNA in blood. The limitations of liquid biopsy in routine diagnostic testing are discussed in this review.

KW - Journal Article

KW - Review

U2 - 10.1111/ddg.13461

DO - 10.1111/ddg.13461

M3 - SCORING: Review article

C2 - 29512873

VL - 16

SP - 405

EP - 414

JO - J DTSCH DERMATOL GES

JF - J DTSCH DERMATOL GES

SN - 1610-0379

IS - 4

ER -